Structural mechanism of SAM-AMP and SAM-AMP2 synthesis by the type III-D2 CRISPR effector complex
The type III-D2 CRISPR-Cas system comprises multiple Cas subunits and a CRISPR RNA, and is likely an evolutionary intermediate between the well-studied type III-A and III-E systems. Here we show that the type III-D2 complex synthesizes two distinct second messengers, SAM-AMP and SAM-AMP2, from S-adenosylmethionine (SAM) and ATP in response to target RNA recognition. We determined cryo-electron microscopy structures of the type III-D2 effector complex in different functional states, providing mechanistic insights into target RNA cleavage and second messenger synthesis. The structures reveal how SAM and ATP are recognized by the Cas10 subunit within the effector complex. Furthermore, our biological data suggest that both SAM-AMP and SAM-AMP2 act on the CorA ancillary effector, inducing growth arrest of infected bacterial cells and thereby conferring immunity. Thus, our study establishes the type III-D2 system as a unique anti-phage defense mechanism that employs both SAM-AMP and SAM-AMP2 as second messengers, expanding the repertoire of second messenger strategies in bacterial defense systems and highlighting the remarkable functional diversity of CRISPR-Cas systems. CRISPR-Cas systems protect bacteria against viruses and other foreign nucleic acids, sometimes involving second messengers that induce antiviral responses. Here, Mitsuda et al. show that the type III-D2 CRISPR-Cas system recognizes a target RNA and synthesizes two distinct second messengers that trigger growth arrest of bacterial cells, thus conferring immunity.
Authors
- Kazuki Kato (ORCID: https://orcid.org/0000-0003-1141-0059)
- Maki Sugaya (ORCID: https://orcid.org/0009-0008-8825-5716)
- Tsuyoshi Osawa (ORCID: https://orcid.org/0000-0002-9479-6665)
- Omar O. Abudayyeh (ORCID: https://orcid.org/0000-0002-7979-3220)
- Hiroshi Nishimasu (ORCID: https://orcid.org/0000-0002-2505-1416)
- Junichiro Ishikawa (ORCID: https://orcid.org/0000-0003-4112-4168)
- Masahiro Hiraizumi (ORCID: https://orcid.org/0000-0002-4340-2937)
- Jonathan S. Gootenberg (ORCID: https://orcid.org/0000-0003-2757-2175)
- Keitaro Yamashita (ORCID: https://orcid.org/0000-0002-5442-7582)
- Naoto Nagahata
- Sae Okazaki
- Yoshihisa Mitsuda
Institutions
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Inamori Foundation (JP)
- Cell and Gene Therapy Catapult (GB)
- Japan Research Institute (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-06-24
- DOI
- https://doi.org/10.1038/s41467-026-74422-0
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- University of Tokyo
- National Institutes of Health
- McGovern Institute for Brain Research, Massachusetts Institute of Technology
- Japan Society for the Promotion of Science
- National Human Genome Research Institute
- Core Research for Evolutional Science and Technology
- ACT-X